Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0000947871-22-000971
Filing Date
2022-09-16
Accepted
2022-09-16 16:23:58
Documents
3
Group Members
ORBIMED CAPITAL GP VI LLCORBIMED CAPITAL LLCORBIMED GENESIS GP LLC

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 1 ss1341724_sc13da.htm SC 13D/A 138071
2 JOINT FILING AGREEMENT ss1341724_ex9901.htm EX-99.1 7733
3 FORM OF LOCK-UP AGREEMENT ss1341724_ex9903.htm EX-99.3 32127
  Complete submission text file 0000947871-22-000971.txt   179500
Mailing Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022
Business Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022 (212) 739-6400
ORBIMED ADVISORS LLC (Filed by) CIK: 0001055951 (see all company filings)

EIN.: 133976876 | State of Incorp.: DE
Type: SC 13D/A

Mailing Address 3415 COLORADO AVE. BOULDER CO 80303
Business Address 3415 COLORADO AVE. BOULDER CO 80303 303-735-8373
Edgewise Therapeutics, Inc. (Subject) CIK: 0001710072 (see all company filings)

EIN.: 821725586 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-92424 | Film No.: 221248318
SIC: 2834 Pharmaceutical Preparations